دورية أكاديمية
أعرض في EDS

Development of m6A/m5C/m1A regulated lncRNA signature for prognostic prediction, personalized immune intervention and drug selection in LUAD.

التفاصيل البيبلوغرافية
العنوان: Development of m6A/m5C/m1A regulated lncRNA signature for prognostic prediction, personalized immune intervention and drug selection in LUAD.
المؤلفون: Ma C; Department of Thoracic Surgery, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China., Gu Z; Department of Thoracic Surgery, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China., Yang Y; Department of Thoracic Surgery, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
المصدر: Journal of cellular and molecular medicine [J Cell Mol Med] 2024 Apr; Vol. 28 (8), pp. e18282.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101083777 Publication Model: Print Cited Medium: Internet ISSN: 1582-4934 (Electronic) Linking ISSN: 15821838 NLM ISO Abbreviation: J Cell Mol Med Subsets: MEDLINE
أسماء مطبوعة: Publication: Oxford, England : Wiley-Blackwell
Original Publication: Bucharest : "Carol Davila" University Press, 2000-
مواضيع طبية MeSH: Biomarkers, Tumor*/genetics , Gene Expression Profiling* , Gene Expression Regulation, Neoplastic* , RNA, Long Noncoding*/genetics , RNA, Long Noncoding*/immunology , RNA Methylation*/genetics , RNA Methylation*/immunology, Humans ; Adenocarcinoma of Lung/genetics ; Adenocarcinoma of Lung/immunology ; Adenocarcinoma of Lung/drug therapy ; Adenocarcinoma of Lung/pathology ; Computational Biology/methods ; Immunotherapy ; Kaplan-Meier Estimate ; Lung Neoplasms/genetics ; Lung Neoplasms/drug therapy ; Lung Neoplasms/mortality ; Lung Neoplasms/immunology ; Lung Neoplasms/pathology ; Nomograms ; Precision Medicine ; Prognosis ; Transcriptome/genetics
مستخلص: Research indicates that there are links between m6A, m5C and m1A modifications and the development of different types of tumours. However, it is not yet clear if these modifications are involved in the prognosis of LUAD. The TCGA-LUAD dataset was used as for signature training, while the validation cohort was created by amalgamating publicly accessible GEO datasets including GSE29013, GSE30219, GSE31210, GSE37745 and GSE50081. The study focused on 33 genes that are regulated by m6A, m5C or m1A (mRG), which were used to form mRGs clusters and clusters of mRG differentially expressed genes clusters (mRG-DEG clusters). Our subsequent LASSO regression analysis trained the signature of m6A/m5C/m1A-related lncRNA (mRLncSig) using lncRNAs that exhibited differential expression among mRG-DEG clusters and had prognostic value. The model's accuracy underwent validation via Kaplan-Meier analysis, Cox regression, ROC analysis, tAUC evaluation, PCA examination and nomogram predictor validation. In evaluating the immunotherapeutic potential of the signature, we employed multiple bioinformatics algorithms and concepts through various analyses. These included seven newly developed immunoinformatic algorithms, as well as evaluations of TMB, TIDE and immune checkpoints. Additionally, we identified and validated promising agents that target the high-risk mRLncSig in LUAD. To validate the real-world expression pattern of mRLncSig, real-time PCR was carried out on human LUAD tissues. The signature's ability to perform in pan-cancer settings was also evaluated. The study created a 10-lncRNA signature, mRLncSig, which was validated to have prognostic power in the validation cohort. Real-time PCR was applied to verify the actual manifestation of each gene in the signature in the real world. Our immunotherapy analysis revealed an association between mRLncSig and immune status. mRLncSig was found to be closely linked to several checkpoints, such as IL10, IL2, CD40LG, SELP, BTLA and CD28, which could be appropriate immunotherapy targets for LUAD. Among the high-risk patients, our study identified 12 candidate drugs and verified gemcitabine as the most significant one that could target our signature and be effective in treating LUAD. Additionally, we discovered that some of the lncRNAs in mRLncSig could play a crucial role in certain cancer types, and thus, may require further attention in future studies. According to the findings of this study, the use of mRLncSig has the potential to aid in forecasting the prognosis of LUAD and could serve as a potential target for immunotherapy. Moreover, our signature may assist in identifying targets and therapeutic agents more effectively.
(© 2024 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.)
References: Front Pharmacol. 2023 Feb 15;14:1113808. (PMID: 36874011)
Cell Biol Int. 2020 Dec;44(12):2524-2531. (PMID: 32869897)
Mol Cancer. 2022 Mar 16;21(1):76. (PMID: 35296338)
Cancer Treat Rev. 2015 May;41(5):431-40. (PMID: 25843228)
Nucleic Acids Res. 2000 Jan 1;28(1):27-30. (PMID: 10592173)
Nat Commun. 2013;4:2612. (PMID: 24113773)
Elife. 2017 Nov 13;6:. (PMID: 29130882)
Anticancer Drugs. 2022 Apr 1;33(4):371-383. (PMID: 35213857)
J Gastrointest Oncol. 2022 Apr;13(2):615-629. (PMID: 35557569)
Theranostics. 2021 Jan 1;11(7):3089-3108. (PMID: 33537076)
Front Genet. 2021 Oct 20;12:714697. (PMID: 34777460)
Front Cell Dev Biol. 2021 Mar 04;9:631259. (PMID: 33763420)
Chest. 2018 Dec;154(6):1416-1423. (PMID: 30189190)
Nat Rev Cancer. 2012 Mar 22;12(4):237-51. (PMID: 22437869)
Biomark Res. 2022 Apr 1;10(1):15. (PMID: 35365216)
J Stat Softw. 2010;33(1):1-22. (PMID: 20808728)
Biostatistics. 2007 Jan;8(1):118-27. (PMID: 16632515)
Int J Oncol. 2020 Dec;57(6):1333-1347. (PMID: 33174014)
Cancer Immunol Res. 2014 Mar;2(3):194-9. (PMID: 24778315)
Cell Death Dis. 2021 Sep 9;12(9):842. (PMID: 34504059)
J Oncol. 2022 Mar 29;2022:1531474. (PMID: 35392434)
Mod Pathol. 2008 May;21 Suppl 2:S16-22. (PMID: 18437168)
Bioinformatics. 2010 Jun 15;26(12):1572-3. (PMID: 20427518)
Front Cell Dev Biol. 2022 Mar 03;10:707405. (PMID: 35309906)
Am J Cancer Res. 2022 Jul 15;12(7):2966-2988. (PMID: 35968342)
Nucleic Acids Res. 2023 Jan 6;51(D1):D587-D592. (PMID: 36300620)
J Gastrointest Oncol. 2021 Aug;12(4):1384-1397. (PMID: 34532096)
Proc Natl Acad Sci U S A. 2022 Jul 12;119(28):e2119038119. (PMID: 35867754)
Clin Cancer Res. 2021 Jan 1;27(1):330-341. (PMID: 33097495)
Genome Med. 2019 May 24;11(1):34. (PMID: 31126321)
Proc Natl Acad Sci U S A. 2022 Mar 22;119(12):e2116251119. (PMID: 35290126)
Cancer Cell Int. 2021 Dec 14;21(1):665. (PMID: 34906142)
Signal Transduct Target Ther. 2021 Feb 21;6(1):74. (PMID: 33611339)
Stat Med. 2013 Dec 30;32(30):5381-97. (PMID: 24027076)
Int J Mol Sci. 2021 Sep 24;22(19):. (PMID: 34638642)
Nat Methods. 2015 May;12(5):453-7. (PMID: 25822800)
Front Immunol. 2022 Jun 27;13:918140. (PMID: 35833147)
Int J Mol Sci. 2021 Sep 30;22(19):. (PMID: 34638933)
Cancer Treat Rev. 2010 Nov;36 Suppl 3:S21-9. (PMID: 21129606)
Nucleic Acids Res. 2015 Apr 20;43(7):e47. (PMID: 25605792)
J Clin Oncol. 2005 Nov 20;23(33):8380-8. (PMID: 16293868)
Mol Cancer. 2020 May 12;19(1):88. (PMID: 32398132)
Methods Mol Biol. 2019;1986:245-253. (PMID: 31115892)
Genome Med. 2017 Apr 19;9(1):34. (PMID: 28420421)
Oncoimmunology. 2016 Apr 25;5(6):e1163462. (PMID: 27471638)
Br J Hosp Med (Lond). 2019 Nov 2;80(11):642-646. (PMID: 31707885)
BMC Bioinformatics. 2012 Dec 24;13:335. (PMID: 23259851)
Clin Chest Med. 2020 Mar;41(1):1-24. (PMID: 32008623)
Nat Med. 2018 Oct;24(10):1550-1558. (PMID: 30127393)
J Cell Mol Med. 2024 Apr;28(8):e18282. (PMID: 38647237)
Br J Cancer. 2017 Nov 21;117(11):1644-1655. (PMID: 29016555)
Brief Bioinform. 2022 Nov 19;23(6):. (PMID: 36151749)
Cells. 2022 Aug 03;11(15):. (PMID: 35954243)
Brief Bioinform. 2022 Sep 20;23(5):. (PMID: 36056743)
Front Immunol. 2021 Jul 02;12:687975. (PMID: 34276676)
Transl Oncol. 2019 Oct;12(10):1323-1333. (PMID: 31352195)
Brief Bioinform. 2017 Jul 1;18(4):558-576. (PMID: 27345524)
Sci Rep. 2020 Sep 15;10(1):15083. (PMID: 32934298)
J Cancer. 2022 Jan 1;13(1):174-183. (PMID: 34976181)
Genes Chromosomes Cancer. 2019 Aug;58(8):578-588. (PMID: 30664300)
Zhongguo Fei Ai Za Zhi. 2020 Nov 20;23(11):961-969. (PMID: 33203198)
Ann Glob Health. 2019 Jan 22;85(1):. (PMID: 30741509)
J Transl Med. 2022 Jan 29;20(1):51. (PMID: 35093098)
Clin Epigenetics. 2023 Apr 7;15(1):60. (PMID: 37029420)
J Clin Lab Anal. 2021 Nov;35(11):e23951. (PMID: 34558724)
BMC Med Res Methodol. 2017 Apr 7;17(1):53. (PMID: 28388943)
J Cell Physiol. 2021 Apr;236(4):2649-2658. (PMID: 32892348)
Genome Biol. 2016 Oct 20;17(1):218. (PMID: 27765066)
Immunity. 2018 Apr 17;48(4):812-830.e14. (PMID: 29628290)
Int J Med Sci. 2019 Jun 10;16(7):981-989. (PMID: 31341411)
Am J Cancer Res. 2015 Jun 15;5(7):2169-79. (PMID: 26328247)
Front Cell Dev Biol. 2021 Jun 29;9:671821. (PMID: 34268304)
Cell Death Dis. 2018 Jan 25;9(2):117. (PMID: 29371589)
Lung Cancer. 2002 Nov;38 Suppl 2:S33-6. (PMID: 12431827)
Genome Med. 2020 Feb 26;12(1):21. (PMID: 32102694)
Brief Bioinform. 2022 Nov 19;23(6):. (PMID: 36094095)
Oncoimmunology. 2021 Jun 23;10(1):1936758. (PMID: 34221700)
J Exp Clin Cancer Res. 2020 Sep 29;39(1):203. (PMID: 32993738)
J Clin Lab Anal. 2022 Sep;36(9):e24636. (PMID: 35949000)
Nat Rev Immunol. 2020 Nov;20(11):651-668. (PMID: 32433532)
BMC Bioinformatics. 2013 Jan 16;14:7. (PMID: 23323831)
Front Oncol. 2021 Jun 09;11:657466. (PMID: 34195072)
Front Immunol. 2023 Sep 29;14:1236444. (PMID: 37841237)
BMC Med Inform Decis Mak. 2022 Apr 6;22(1):92. (PMID: 35387672)
Protein Sci. 2019 Nov;28(11):1947-1951. (PMID: 31441146)
Ann Thorac Surg. 1984 Aug;38(2):133-9. (PMID: 6087748)
Genome Biol. 2016 Aug 22;17(1):174. (PMID: 27549193)
Cell Signal. 2021 May;81:109934. (PMID: 33545231)
J Cell Physiol. 2021 May;236(5):3244-3256. (PMID: 33135190)
Front Immunol. 2022 Sep 21;13:967921. (PMID: 36211353)
Genome Biol. 2017 Nov 15;18(1):220. (PMID: 29141660)
Ann Oncol. 1995;6 Suppl 3:S57-60. (PMID: 8616118)
J Gastrointest Oncol. 2021 Aug;12(4):1860-1872. (PMID: 34532134)
Nat Genet. 2019 Feb;51(2):202-206. (PMID: 30643254)
Front Cell Dev Biol. 2021 Nov 30;9:767668. (PMID: 34917614)
Brief Bioinform. 2021 May 20;22(3):. (PMID: 32789496)
Front Oncol. 2022 May 30;12:882292. (PMID: 35712502)
Genes Dis. 2022 Jan 29;10(2):495-504. (PMID: 37223516)
Front Cell Dev Biol. 2021 Nov 30;9:718974. (PMID: 34917609)
Cancer Biol Med. 2022 Mar 08;:. (PMID: 35254013)
فهرسة مساهمة: Keywords: drug prediction; immunotherapy; lncRNA signature; lung adenocarcinoma; m6A/m5C/m1A; prognosis
المشرفين على المادة: 0 (Biomarkers, Tumor)
0 (RNA, Long Noncoding)
CLE6G00625 (N-methyladenosine)
تواريخ الأحداث: Date Created: 20240422 Date Completed: 20240429 Latest Revision: 20240509
رمز التحديث: 20240509
مُعرف محوري في PubMed: PMC11034373
DOI: 10.1111/jcmm.18282
PMID: 38647237
قاعدة البيانات: MEDLINE
الوصف
تدمد:1582-4934
DOI:10.1111/jcmm.18282